Global Furniture Brand DEDON Adopts COREnergy’s Sunshine Plan

DEDON Manufacturing becomes COREnergy’s first Sunshine Plan customer through a two-year retail electricity supply agreement.

Distressed Denim Meets Brocade In Marques’Almeida’s Spring/Summer 2027

Marques’Almeida brings rawness and refinement into the same frame for Spring/Summer 2027, pairing sculptural proportions with the brand’s instinctively undone approach.

Pre-Order And Own The Latest iPhone 18 Pro And iPhone 18 Pro Max For As Low As PHP137 Per Day With Home Credit

Home Credit Philippines gives Filipinos more flexible ways to pre-order and own the latest iPhone 18 Pro models.

Miguel Vieira: Spring-Summer 2027 Womenswear Collection “Back To Black”

Black becomes a language of its own as the Spring/Summer 2027 collection brings sculptural flowers, precise tailoring, and fluid silhouettes into focus.

Oxford University Vaccine Trials To Resume

Trials of a coronavirus vaccine being developed by Oxford University and British drug manufacturer AstraZeneca will resume after being paused.

Oxford University Vaccine Trials To Resume

122
122

How do you feel about this story?

Express Your Reaction
Like
Love
Haha
Wow
Sad
Angry

Trials of a coronavirus vaccine being developed by Oxford University and British drug manufacturer AstraZeneca will resume after being paused, they said in a statement on Saturday.

The trials had been paused last week after a participant fell ill.

According to the vaccine partners, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) said trials could resume, after a committee of theirs inspected safety data.

Oxford University said in a statement: “Globally some 18,000 individuals have received study vaccines as part of the trial. In large trials such as this, it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety.”

AstraZeneca said in a statement: “The UK committee has concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume.” (PNA)